- Home
- EGY vs MBX Comparison
EGY vs MBX Comparison
Compare EGY & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- MBX
- Stock Information
- Founded
- EGY 1985
- MBX 2018
- Country
- EGY United States
- MBX United States
- Employees
- EGY N/A
- MBX N/A
- Industry
- EGY Oil & Gas Production
- MBX
- Sector
- EGY Energy
- MBX
- Exchange
- EGY Nasdaq
- MBX NYSE
- Market Cap
- EGY 340.3M
- MBX 379.7M
- IPO Year
- EGY N/A
- MBX 2024
- Fundamental
- Price
- EGY $3.84
- MBX $9.63
- Analyst Decision
- EGY
- MBX Strong Buy
- Analyst Count
- EGY 0
- MBX 5
- Target Price
- EGY N/A
- MBX $37.40
- AVG Volume (30 Days)
- EGY 1.1M
- MBX 227.0K
- Earning Date
- EGY 08-05-2025
- MBX 08-16-2025
- Dividend Yield
- EGY 6.53%
- MBX N/A
- EPS Growth
- EGY N/A
- MBX N/A
- EPS
- EGY 0.56
- MBX N/A
- Revenue
- EGY $489,162,000.00
- MBX N/A
- Revenue This Year
- EGY N/A
- MBX N/A
- Revenue Next Year
- EGY $24.62
- MBX N/A
- P/E Ratio
- EGY $6.89
- MBX N/A
- Revenue Growth
- EGY 3.02
- MBX N/A
- 52 Week Low
- EGY $3.00
- MBX $4.81
- 52 Week High
- EGY $7.43
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- EGY 64.80
- MBX N/A
- Support Level
- EGY $3.30
- MBX N/A
- Resistance Level
- EGY $4.04
- MBX N/A
- Average True Range (ATR)
- EGY 0.15
- MBX 0.00
- MACD
- EGY 0.05
- MBX 0.00
- Stochastic Oscillator
- EGY 81.66
- MBX 0.00
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.